Lyell Immunopharma, Inc. — Director's Dealing 2022

Mar 29, 2022

SEC Form 3 — Initial Statement of Beneficial Ownership

Issuer: Lyell Immunopharma, Inc. (LYEL)
CIK: 0001806952
Period of Report: 2022-03-23

Reporting Person: Albertson Tina M. (Chief Medical Officer)

Holdings (Derivative)

Security	Exercise Price	Expiration	Underlying	Shares	Ownership
Option (right to buy)	$5.81	2030-08-09	Common Stock (500000)		Direct
Option (right to buy)	$5.96	2030-11-16	Common Stock (400000)		Direct
Option (right to buy)	$5.98	2032-03-15	Common Stock (600000)		Direct

Footnotes

F1: 1/4 of the option shares vested on July 1, 2021, with the remaining option shares to vest in equal monthly installments over the following thirty-six months.

F2: The option shares vest in equal monthly installments over the forty-eight months following December 1, 2020.

F3: 12.5% of the option shares shall vest on August 9, 2022, with the remaining option shares to vest in equal monthly installments over the following forty-two months.